Intrauterine Contraceptive Devices Market Updates

Q: What is the key market trend for Intrauterine Contraceptive Devices Market?

Increasing Demand for Non-Hormonal Contraceptives: The demand for non-hormonal intrauterine contraceptive devices is increasing rapidly as more women opt for hormone-free options. Devices such as the Copper IUD are becoming popular due to their long-term nature but non-interference with hormonal balances. This trend is especially strong in those markets with consumers who are health-conscious and choose non-invasive, hormone-free products to escape side effects of hormonal birth control. The market is reacting to the need for more comfort and design in non-hormonal IUDs to meet this increasing demand, and they are now a competitive product on global markets.

Q: Which region accounted for the largest share in Intrauterine Contraceptive Devices Market?

What makes North America the top market for Intrauterine Contraceptive Devices in 2024?

Intrauterine Contraceptive Devices Market News

in Intrauterine Contraceptive Devices

Medicines360 made strategic alliances with DKT WomanCare in January 2024 to introduce the hormonal IUD Avibela™ into additional markets with increased access. The alliance is geared toward increasing access to contraception at low price in less-resourceful markets in line with Medicines360's vision to empower women's health worldwide. The alliance will drive distribution networks and support public health programs for reproductive and family health.

In 2024, OCON Healthcare made public the release of positive long-term efficacy and safety findings for its non-hormonal IUB Ballerine contraceptive. Findings, based on more than 100,000 users, showed high satisfaction and low complication rates, affirming the device's reputation as a trusted non-hormonal contraceptive. The release is consistent with OCON's mission to deliver innovative and effective reproductive healthcare solutions.

Bayer has invested more than €400 million in 2024 to expand access to modern contraception. The company will establish a cutting-edge production site in Costa Rica manufacturing long-acting reversible contraceptives (LARCs), such as hormonal IUDs. The site will be used to supply LARCs to low- and middle-income countries in line with Bayer's ambition to reach 100 million women and girls with access to family planning by the year 2030.

FAQs

Global Intrauterine Contraceptive Devices Market size was valued at USD 4.4 billion in 2023 and is poised to grow from USD 4.6 billion in 2024 to USD 6.6 billion by 2032, growing at a CAGR of 4.6% during the forecast period (2025-2032).

The market for intrauterine contraceptive devices (IUD) is highly competitive with established vendors and new-generation companies. Bayer AG possesses the largest market share of approximately 35% because of its differentiated hormonal IUD portfolio, i.e., Mirena, Skyla, and Kyleena, which cater to different patient segments. Merck & Co. possesses the second with approximately 25% market share because of its strong business in hormonal and copper IUD markets, especially in emerging markets. Firms are emphasizing product innovation, i.e., concentrating on the development of small, flexible IUDs for nulliparous women and growing in emerging markets in strategic alliances and public education campaigns. 'Teva Pharmaceutical Industries Ltd. (Jerusalem)', 'Bayer (Germany)', 'EUROGINE (Spain)', 'CooperSurgical Inc. (US)', 'Pfizer Inc. (US)', 'HLL Lifecare Limited (Thiruvananthapuram)', 'OCON Medical Ltd. (Israel)', 'Prosan International BV (Netherlands)', 'Melbea Innovations (Hungary)', 'Allergan, Merck & Co., Inc. (US)', 'DKT International (US)', 'Medisafe Distribution Inc. (Canada)', 'Medicines360 (US)', 'Pregna International Limited (India)', 'Egemen International (Turkey)'

Increasing uptake of long-acting reversible forms of contraception, including intrauterine contraceptive devices (IUDs), is one of the key market drivers. Women are increasingly opting for methods that are effective, low maintenance, and long-acting in preventing pregnancy. IUDs are over 99% effective and have a duration of 3–10 years, depending on the type, and hence provide a convenient option to short-term or daily contraceptives. Secondly, healthcare professionals actively prescribe LARC methods as a first-line contraceptive method and hence propel the use of IUDs. Awareness campaigns regarding the convenience and reliability of LARCs are leading to greater acceptability among various demographic and geographical segments.

Increasing Demand for Non-Hormonal Contraceptives: The demand for non-hormonal intrauterine contraceptive devices is increasing rapidly as more women opt for hormone-free options. Devices such as the Copper IUD are becoming popular due to their long-term nature but non-interference with hormonal balances. This trend is especially strong in those markets with consumers who are health-conscious and choose non-invasive, hormone-free products to escape side effects of hormonal birth control. The market is reacting to the need for more comfort and design in non-hormonal IUDs to meet this increasing demand, and they are now a competitive product on global markets.

What makes North America the top market for Intrauterine Contraceptive Devices in 2024?